000 01514 a2200325 4500
005 20250517033201.0
264 0 _c20160217
008 201602s 0 0 eng d
022 _a1548-8756
024 7 _a10.14694/EdBook_AM.2015.35.76
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aPostow, Michael A
245 0 0 _aManaging immune checkpoint-blocking antibody side effects.
_h[electronic resource]
260 _bAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
_c2015
300 _a76-83 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650 0 4 _aAntibodies, Monoclonal
_xadverse effects
650 0 4 _aAntineoplastic Agents
_xadverse effects
650 0 4 _aCTLA-4 Antigen
_xantagonists & inhibitors
650 0 4 _aChemical and Drug Induced Liver Injury
_xdrug therapy
650 0 4 _aColitis
_xchemically induced
650 0 4 _aDiarrhea
_xchemically induced
650 0 4 _aGranulocyte-Macrophage Colony-Stimulating Factor
_xtherapeutic use
650 0 4 _aHumans
650 0 4 _aOpportunistic Infections
_xdrug therapy
650 0 4 _aProgrammed Cell Death 1 Receptor
_xantagonists & inhibitors
650 0 4 _aRecombinant Proteins
_xtherapeutic use
773 0 _tAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
_gp. 76-83
856 4 0 _uhttps://doi.org/10.14694/EdBook_AM.2015.35.76
_zAvailable from publisher's website
999 _c24919021
_d24919021